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Results
Median FU was 36 months and 25% of patients had a FU of at least 
60 months. The 5y-CIf of cGVHD was 58%. Sex mismatch (F>M) 
increased risk of cGVHD (HR: 1.41, P=.02). The 5y-CIf of relapse was 
34% and was higher with MRD than MUD (39% vs. 24%, P=.038). 
Only MRD=60y resulted in significant higher risk of relapse than 
MUD (HR 2.46, P=.006) while MRD <60y had similar risk. The 
5y-NRM was 26%. MUD vs. MRD was associated with higher NRM 
(HR: 1.84, P=.005). The 5y-OS was 46% and was similar with MUD and 
MRD. MRD=60y appeared to have notable low 5y-OS (6%, 6%). 
Transplantation from MRD=60y was associated with higher risk of 
late (=18 months) mortality (HR: 4.36, P=.007) than MUD (Fig. 1).
Conclusion
After PB SCT, MUD provided higher NRM but better disease control 
and similar OS than MRD. A sex mismatched donor (F>M) was 
associated with higher risk of cGVHD. We observed notable poor 
outcome for patients transplanted with MRD=60y. One may thus 
question HCT with old MRD when a younger MUD is available.
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with rapamycin for treatment of chronic Graft-
versus-Host disease
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Background
Chronic graft-versus-host disease (cGvHD) occurs up to 50 % in 
long-term survivors and is one of the main complications after allo-
HSCT. Donor CD4+ and regulatory T cells (Tregs) are the key-players 
in its pathogenesis. Moreover, rapamycin, a mTor inhibitor, could 
suppress activation and proliferation of effector T cells and expand 
in vitro Tregs.
Aims
To assess the combined treatment of Tregs and rapamycin injections 
in vivo for cGvHD.
Results
Lethally irradiated Balb/C mice were injected with 10x106 bone 
marrow cells and 70x106 splenocytes from B10.D2 donor mice. 
Twenty-one days later, the treatments were started (PBS, rapamycin 
1 mg/kg/Day, Tregs 1.106 cells or rapamycin 1 mg/kg/Day + Tregs 
1.106 cells). No significant differences were observed between 
survival of PBS-treated (Median: 40 days) compared to rapamycin 
alone or Tregs alone (Median: 46 days, p=0.1390; Median: 46 days, 
p=0.2450 respectively) while survival of mice receiving rapamycin 
and Tregs was increased (p=0.0074). Twenty-one days after starting 
the treatment, number of CD4+ T cells was significantly decreased 
in Tregs (37.0010.00; p=0.0303) and Tregs + rapamycin-treated 
(27.0056.00; p=0.0293) mice compared to PBS mice (95.00100.50). 
Proliferation of CD4+ T cells (assessed by flow cytometry unsing 
Ki67) was only significantly decreased in Tregs + rapamycin-treated 
mice (19.609.17 versus 36.8012.40; p=0.0043). Number of cells per 
micorliters and proliferation of both effector and central memory 
CD4+ T cells were significantly decreased in Tregs + rapamycin-treated 
mice compared to PBS mice. Number of CD8+ T cells was significantly 
decreased in rapamycin (56.0063.00; p=0.0082) and Tregs + rapamycin-
treated (58.5077.80; p=0.0082) mice compared to PBS mice 
(144.00103.80). Despite a significant increase in the percentage of 
Tregs in rapamycin 1 mg/kg/Day (20.3043.15; p=0.0519), Tregs 1.106 
cells (95.6559.75; p=0.0190) or rapamycin 1 mg/kg/Day + Tregs 1.106 
cells groups (29.6066.30; p=0.0043) compared to PBS-treated mice 
(15.353.80), no significant differences were seen in the number per 
micorliter.
Conclusion
Regulatory T cells injection combined with rapamycin daily 
administration seems to treat cGvHD in vivo by combining the 
beneficial effect of these treatments.
O.5  In vitro generation of antigen-specific T-cells 
from hematopoietic progenitor cells: a new and 
promising immunotherapeutic strategy
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Introduction
Transfer of high-affinity tumor-specific T-cell receptor (TCR) genes 
into polyclonal peripheral blood T-cells is an attractive immuno-
therapeutic strategy against malignancies and viruses. However, 
inappropriate crosspairing between introduced and endogenous 
TCR chains can result in suboptimal activity and unpredicted, 
potentially harmful antigen-specificities. Efficient in vitro generation 
of antigen-specific T-cells from CD34+ hematopoietic progenitor 
cells (HPCs) may eliminate these restrictions, based on the 
hypothesis that early introduction of rearranged TCRa and TCR 
chains might result in allelic exclusion of the endogenous TCRa 
and/or TCR locus. We and others have previously shown that HPCs 
commit to the T-cell lineage and become CD4+CD8+ double positive 
(DP) precursors when cultured on OP9-DL1 stromal cells.
Results
CD34+ HPCs from human postnatal thymus were retrovirally 
transduced to express the TCRa and TCR chains of HLA-A2 restricted 
TCRs recognising epitopes of cytomegalovirus (CMV pp65) or 
Wilms’ tumour 1 (WT1). Differentiation in transduced cultures was 
studied. We confirmed earlier reports showing that terminal 
maturation of TCR-transduced DP cells to mature CD8 single 
positive (SP) cells occurs, albeit at low efficiency. We hypothesised 
that the observed maturation involved selection by TCR binding to 
HLA class I /peptide complexes present in culture. Therefore, we 
added the respective agonist peptide to the cultures. This induced 
rapid phenotypical maturation to CD27+CD1- of the majority of TCRa+ 
DP cells. Antigen presentation by HLA-A2+ dendritic cells, HLA-A2+ 
tumour cell lines, and even cross-presentation by HLA-A2+ T-cell 
progenitors, but not by HLA-A2- cells, induced this maturation process.
The mature cells are CD8a+ or CD8aa+SP and CD4-CD8- cells. These 
T-cells expanded upon culture with PHA and IL-2 on irradiated 
feeders, indicating functionality. Upon activation, specific killing of 
T2 cells loaded with agonist peptide, was observed. In vitro 
generated T-cells showed clearly higher percentages of tetramer-
positive cells compared with TCR-transduced peripheral blood 
T-cells. Spectratyping revealed major inhibition of endogenous 
TCRa and TCR gene rearrangements.
Conclusion
In vitro generation of functional antigen-specific T-cells from CD34+ 
HPCs is a promising new immunotherapeutic strategy.
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Background
Graft-Versus-Host-Disease (GVHD) is a life-threatening complication 
of allogeneic hematopoietic stem cell transplantation (HSCT). 
Animal models have demonstrated that Treg infusion could prevent 
otherwise lethal GVHD in mice given grafts from MHC-disparate 
donors. Here, we assessed the ability of clinical-grade isolated 
human Treg to attenuate experimental xenogeneic GVHD.
Material and methods
Human Treg were isolated from cytapheresis products with the 
Miltenyi CliniMacs system using a two steps procedure (CD8 and 
CD19 depletion followed by CD25 positive selection) in six 
independent experiments with six different healthy volunteer 
donors. Sub-lethally (2.5 Gy) irradiated NSG mice were given 2x106 
cytapheresis product cells i.v. without (PBMC group) or with 1x106 
Tregs (PBMC+Treg group), while other NSG mice received only 
2x106 Treg (also in i.v.; Treg group). Mice in terminal stage GVHD 
were euthanised.
Results
After the selection, we obtained a CD25 enriched fraction including 
a median of 1.81 x108 cells and containing 59 +/- 6% or 66 +/- 6% 
Treg defined as either CD45+CD4+CD25HighFoxP3+ cells or CD45+CD4+ 
CD25highCD127low cells. In all experiments but the last (a technical 
problem dramatically impacts the efficiency of this selection), Treg 
co-transfusion significantly delayed death from xenogeneic GVHD. 
Specifically, median survivals in PBMC versus PBMC+Treg mice were 
30 vs 56 days (p=0.015), 123.5 vs >162 days (p=0.23), 25.5 vs 70 days 
(p=0.012), 13 vs 16 days (p=0.038), 27 vs 49 days (p=0.061), and 46 
vs 47 days (p=0.338) respectively. Further, none of the mice given 
only Treg experienced signs of GVHD, while, interestingly, the CD4+ 
cells found in these mice 27 days after transplantation were mainly 
conventional T cells (CD25+FoxP3+ cells in human CD4+ total cells 
were only 2.1%, 3.1% and 17.7% in spleen, bone marrow and 
blood, respectively while 80.2% were grafted).
Conclusion
Treg infusion delayed the occurrence of xenogeneic GVHD without 
showing any toxicity in this murine model.
O.7  Erythropoietin therapy after allogeneic 
hematopoietic cell transplantation : a prospective 
randomised trial
A. Jaspers, F. Baron, E. Willems, K. Hafraoui, G. Vanstraelen, C. Bonnet, 
Y. Beguin
CHU de Liège
Based on the impairment of erythropoietin production after allo-
geneic hematopoietic cell transplantation (HCT), we previously 
reported in a phase-2 trial that recombinant human erythropoietin 
(rhEPO) therapy was very efficient when started one month after 
transplantation. We also demonstrated that anemia after non-
myeloabalative (NM) HCT was less sensitive to rhEPO therapy than 
after conventional allogeneic HCT. This prompted us to confirm 
these findings in a prospective randomised trial.
One hundred and thirty-one patients were randomised (1:1) between 
no treatment (arm 1) or erythropoietin (Neorecormon) at the dose 
of 500 U/kg/week (arm 2). Once the target Hb (13g/dL) has been 
attained, the dose of rhEPO was reduced by half, while it was 
withheld when Hb was = 14g/dL. Cohort A included 42 patients on 
day 28 after myeloablative HCT, cohort B 39 patients on day 28 
after NMHCT, and cohort C 50 patients on day 0 of NMHCT. Primary 
endpoints included proportion of complete correctors (i.e. patients 
reaching Hb = 13g/dL) and median time to achieve Hb correction in 
each arm.
The proportion of complete correctors before day 126 post-
transplant was 0% in group 1A vs 52.4% in group 2A, 0% in group 
1B vs 69.5% in group 2B and 19.1% in group 1C vs 70.2% in group 
2C. Median time to achieve Hb = 13g/dL was not reached in group 
1B vs 49 days in group 2B; 363 and 59 days in groups 1A and 1B 
respectively and 363 and 87 days in groups 3A and 3B respectively 
(figure 1). Hb evolution in each group is shown in figure 2. Seventy-
one patients (47/62 in control groups and 24/57 in treated groups, 
p=0.0003) required red blood cell transfusions. The difference was 
most pronounced in cohort B. There was no difference in rates of 
thrombo-embolic events or other complications between the two 
arms. In conclusion, this is the first trial to demonstrate that EPO 
therapy hastens erythroid recovery and decreases transfusion 
requirements when started one month after allogeneic HCT.
O.8  The value of asparaginase intensification 
for children with low and average risk acute 
lymphoblastic leukemia (ALL) and non-Hodgkin 
lymphoma (NHL) in the EORTC-CLG Randomized 




Asparaginase (ASP) is an essential component in combination chemo-
therapy for childhood ALL. However, the optimal number of ASP-
administrations is still unknown. We conducted a randomised 
phase III trial comparing conventional E.coli-ASP-regimen (short-ASP, 
12 doses) with prolonged E.coli-ASP-therapy (long-ASP, 24 doses).
Methods
The EORTC-CLG 58951 trial was open to de novo ALL or NHL 
patients (pts) <18y. This study addressed two main randomised 
questions. The first evaluated the value of dexamethasone (DEX, 
6mg/m/d) vs prednisolone (PRED, 60mg/m/d) in induction for all 
patients. In the second question all non-VHR pts were randomised 
for either short- or long-ASP. All patients received 8x10000U/m in 
induction. In the short-ASP-arm patients received 4x10000U/m in 
reinduction; patients in the long-ASP-arm received 8x5000U/m E.
coli-ASP-injections in consolidation and eight (4x10000U/m + 4x 
5000U/m) in reinduction. Patients with grade =2 allergy to E.coli-
ASP were switched to equivalent doses of Erwinia or PEG-ASP.
Results
Between 12/1998 and 08/2008, 1552 patients were randomly assigned 
to receive long-ASP (n=775) or short-ASP (n=777). The 8-year DFS rate 
was 87.0% in the long-ASP and 84.2% in short-ASP-group (hazard 
ratio (HR) = 0.87, 95% CI 0.66-1.14, 2-sided logrank p=0.30). The 8-year 
OS rate was comparable in both treatment arms: 92.6% in the long-
ASP-group and 91.3% in the short-ASP-group (HR = 0.89, 95% CI 0.61- 
1.29, p=0.53). Similar treatment differences were observed in each 
risk group, in PRED vs DEX arm, and B- and T-lineage ALL-patients.
The incidence of grade 3-4 infection was higher in the long- versus 
short-ASP-group during consolidation (25.2% vs 14.5%) and re-
induction (22.6% vs 15.9%). This difference was more pronounced 
in patients who received DEX in induction (27.3% vs 11.6%). During 
the whole treatment period, the incidence of grade 2-4 allergy was 
32.8% in the long-ASP-arm and 21.8% in the short-ASP-arm.
Conclusion
At long follow-up prolonged E.coli asparaginase therapy in conso-
